I am the driving force behind Tribune Updates with a vision to broaden the company’s readership throughout 2016. I am an editor and reporter of “Healthcare” category.
Address: 1208 Jewell Road Eagan, MN 55121, USA
Phone: (+1) 612-598-3663
Latest posts by Richard Bower (see all)
- Notable Runner: Blackstone Mortgage Trust Inc. (NYSE: BXMT) - January 28, 2020
- Eye-Catching Stock to Track: The Travelers Companies Inc. (NYSE: TRV) - January 25, 2020
- Stock in the News: Lincoln National Corporation (NYSE: LNC) - January 24, 2020
SAN DIEGO, November 15, 2019 – Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) showed the bearish trend with a lower momentum of -6.34% to $9.01. The company traded total volume of 121.226K shares as contrast to its average volume of 77.98K shares. The company has a market value of $140.01M and about 14.60M shares outstanding.
Arcturus Therapeutics Holdings Inc. (ARCT) reported collaboration revenue of $10.20M during the quarter ended June 30, 2019, compared to $2.40M in the quarter ended June 30, 2018. Approximately $7.0M in revenues was non-recurring in the 2019 second quarter
Operating Expenses: Operating expenses were $10.70M in the quarter ended June 30, 2019, compared to $12.50M in the quarter ended June 30, 2018. The June 30, 2018 quarter included approximately $5.0M in proxy-related expenses.
Net Loss: Net loss for the quarter ended June 30, 2019 was approximately $0.70M, or ($0.07) per basic and diluted share, compared with a net loss of $10.00M, or ($0.99) per basic and diluted share, in the quarter ended June 30, 2018.
Cash: At June 30, 2019, Arcturus had cash and cash equivalents totaling $55.80M, compared to cash, cash equivalents of $36.70M at December 31, 2018.
The Company offered net profit margin of -85.40%. ROE was recorded as -167.80% while beta factor was 2.50. The stock, as of recent close, has shown the weekly upbeat performance of 8.33% which was maintained at 144.15% in this year.